Clinical Trial

Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a phase Ib study with a safety lead-in (n = 6 per arm) evaluating combinatorial DPV-001 + sequenced PD-1 blockade, with or without GITR agonist, in recurrent or metastatic HNSCC.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2020-07-09; most recent amendment 2026-04-07.
Status change: Active, Not Recruiting → Recruiting 2024-06-18
Status change: Recruiting → Active, Not Recruiting 2023-07-28
Status change: Not Yet Recruiting → Recruiting 2021-09-01
Trial Details
NCT Number NCT04470024
Lead Sponsor Providence Health & Services
Conditions Cancer of the Head and Neck
Enrollment 56 participants
Start Date 2021-08-05
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-13